NasdaqCM - Delayed Quote • USD
BIOLASE, Inc. (BIOL)
At close: April 18 at 4:00 PM EDT
Pre-Market: 8:41 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -0.17 | -0.05 | -0.32 | -0.11 |
| Low Estimate | -0.21 | -0.08 | -0.4 | -0.13 |
| High Estimate | -0.13 | -0.02 | -0.24 | -0.09 |
| Year Ago EPS | -18 | -8.93 | -29.44 | -0.32 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | 10M | 14.09M | 51.5M | 55.5M |
| Low Estimate | 9.7M | 13.79M | 51M | 53.6M |
| High Estimate | 10.49M | 14.3M | 52M | 57.21M |
| Year Ago Sales | 10.47M | 14.29M | 49.16M | 51.5M |
| Sales Growth (year/est) | -4.50% | -1.40% | 4.80% | 7.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -19.67 | -5.33 | -1.85 | -2.55 |
| EPS Actual | -18 | -8.93 | -3.89 | -1.76 |
| Difference | 1.67 | -3.6 | -2.04 | 0.79 |
| Surprise % | 8.50% | -67.50% | -110.30% | 31.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.17 | -0.05 | -0.32 | -0.11 |
| 7 Days Ago | -0.17 | -0.05 | -0.32 | -0.11 |
| 30 Days Ago | -0.89 | -0.47 | -1.84 | -0.1 |
| 60 Days Ago | -1.8 | -1.23 | -4.88 | -1.52 |
| 90 Days Ago | -1.8 | -1.23 | -4.88 | -1.52 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 3 | 3 | 3 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | BIOL | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 99.10% | -- | -- | 0.80% |
| Next Qtr. | 99.40% | -- | -- | 9.60% |
| Current Year | 98.90% | -- | -- | 4.50% |
| Next Year | 65.60% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 20.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 13.59% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | Ascendiant Capital: Buy to Buy | 4/1/2024 |
| Maintains | Benchmark: Speculative Buy to Speculative Buy | 3/22/2024 |
Related Tickers
MOTS Motus GI Holdings, Inc.
0.1735
0.00%
SINT Sintx Technologies, Inc.
0.0400
+7.24%
ZOM Zomedica Corp.
0.1293
-0.77%
HSCS Heart Test Laboratories, Inc.
0.1085
+7.43%
INBS Intelligent Bio Solutions Inc.
2.8000
+5.26%
DYNT Dynatronics Corporation
0.5563
-4.91%
OPGN OpGen, Inc.
0.6161
+2.70%
TIVC Tivic Health Systems, Inc.
1.1570
+4.23%
BSGM BioSig Technologies, Inc.
1.5400
-5.52%
VVOS Vivos Therapeutics, Inc.
2.6600
0.00%